Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes
Cohen, Jonathan, Palumbo, Alison, Wing, Jason, Heinrich, Michael C.Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1768380
Date:
May, 2020
File:
PDF, 768 KB
2020